A simple, sensitive, 30-min assay for the detection of herpes simplex virus (HSV) and varicella-zoster virus (VZV) antigens in clinical specimens is described. The assay utilizes a filter manifold, biotinylated monoclonal antibodies, streptavidin-horseradish peroxidase conjugate, and the substrate aminoethylcarbazole. The method stains infected cells and cell debris a bright red and is easily interpreted with a dissecting microscope. Reconstruction experiments indicated that as few as two virus-infected cells per swab could be detected. This was equivalent to an infectivity titer of 29 to 160 50% tissue culture infective doses per infected cell and 250 times more sensitive than an enzyme immunofiltration assay which detects a soluble reaction product. Clinical swab specimens collected from ocular, oral, skin, and genital lesions were cultured for virus, and the remaining cell debris was immobilized on glass fiber filters and stained for the presence of virus antigens. Of 71 HSV culture-positive specimens, 66 (93%) were positive for HSV antigens. All of nine VZV culture-positive specimens were positive for VZV antigens. Of 98 culture-negative specimens, 7 were positive for either HSV (n = 3) or VZV (n = 4) antigens.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC265911 | PMC |
| http://dx.doi.org/10.1128/jcm.25.2.416-420.1987 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
VZV IE4 downregulates cellular surface MHC-I via sequestering it to the Golgi complex.
Cell Mol Life Sci
December 2024
Department of Microbiology, Immunology and Infectious Diseases, University of Calgary, Calgary, AB, Canada.
Varicella-zoster virus (VZV) infection downregulates surface major histocompatibility complex class I (MHC-I) expression and retains MHC-I in the Golgi complex of infected cells. However, the underlying mechanism is not fully understood. The VZV IE4 protein is a multifunctional protein that is essential for VZV infection.
View Article and Find Full Text PDFBroad Analysis of Serum and Intrathecal Antimicrobial Antibodies in Multiple Sclerosis Underscores Unique Role of Epstein-Barr Virus.
Neurol Neuroimmunol Neuroinflamm
January 2025
From the Department of Neurology (F.P., C.O., P.S., M.N., K.R.), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin; Institute for Experimental Immunology (D.W., T.L., K.S., E.G.-G.), affiliated with EUROIMMUN Medizinische Labordiagnostika AG, Luebeck; and Molecular Neuroimmunology Group (B.W., S.J.), Department of Neurology, University of Heidelberg, Germany.
Article Synopsis
- - The study investigates the relationship between the Epstein-Barr virus (EBV) and multiple sclerosis (MS) by analyzing the presence of antibodies against EBV and other common microbes in patients with MS, revealing a universal EBV seroprevalence among participants.
- - A total of 50 MS patients were tested for antibodies in their cerebrospinal fluid (CSF) and serum, finding that while all patients were EBV positive, the production of specific antibodies in the CSF was significantly lower for EBV compared to other viruses like measles and VZV.
- - The results indicate that even though almost all MS patients have been exposed to EBV, the actual production of antibodies against EBV in the central
Optimal timing of recombinant herpes zoster virus vaccination for a JAK inhibitor treatment in rheumatoid arthritis: a multicentre, open-label, randomised comparative study (STOP-HZ study): study protocol.
BMJ Open
November 2024
Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
Article Synopsis
- JAK inhibitors, used to treat rheumatoid arthritis, can increase the risk of herpes zoster, prompting the need for appropriate vaccination timing with the recombinant zoster vaccine (RZV).
- The STOP HZ study aims to determine whether initiating tofacitinib at the first or second RZV vaccination affects patients' immune response (IgG titers and T cell response) and disease activity.
- This multicenter, randomized study will recruit 60 patients and measure various treatment outcomes, all while conforming to ethical guidelines and requiring informed consent.
Truncated VZV gE Induces High-Titer Neutralizing Antibodies in Mice.
Vaccines (Basel)
October 2024
National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.
A contemporary public health challenge is the increase in the prevalence rates of herpes zoster (HZ) worldwide. In this work, the gE gene structure was analyzed using bioinformatics techniques, and three plasmids of varying lengths, tgE537, tgE200, and tgE350, were expressed in Chinese hamster ovary (CHO) cells. These proteins were used to immunize BALB/c mice with Al/CpG adjuvant; ELISPOT and FCM were used to evaluate cellular immunity; and ELISA, VZV microneutralization, and FAMA assays were performed to detect antibody titers.
View Article and Find Full Text PDFStructures of the Varicella Zoster Virus Glycoprotein E and Epitope Mapping of Vaccine-Elicited Antibodies.
Vaccines (Basel)
September 2024
GSK, Rockville, MD 20850, USA.
Varicella zoster virus (VZV) is the causative agent for chickenpox and herpes zoster (HZ, shingles). HZ is a debilitating disease affecting elderly and immunocompromised populations. Glycoprotein E (gE) is indispensable for viral replication and cell-to-cell spread and is the primary target for anti-VZV antibodies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!